| 12/06/25 | GSK | 11:00:00 | 12 Jun 2025 | | GSK | Director/PDMR Shareholding | GSK plc | PRN |
| 20/02/24 | GSK | 09:01:24 | 20 Feb 2024 | | GSK | Julie Brown - External Appointment | GSK PLC | RNS |
| 19/02/24 | GSK | 15:30:00 | 19 Feb 2024 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 15/02/24 | GSK | 15:32:43 | 15 Feb 2024 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 15/02/24 | GSK | 07:00:02 | 15 Feb 2024 | | GSK | GSK completes acquisition of Aiolos Bio | GSK PLC | RNS |
| 13/02/24 | GSK | 16:45:17 | 13 Feb 2024 | | GSK | Director/PDMR Shareholding - Replacement | GSK PLC | RNS |
| 13/02/24 | GSK | 15:40:00 | 13 Feb 2024 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 13/02/24 | GSK | 15:35:00 | 13 Feb 2024 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 13/02/24 | GSK | 15:30:00 | 13 Feb 2024 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 12/02/24 | GSK | 15:39:23 | 12 Feb 2024 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 12/02/24 | GSK | 15:38:33 | 12 Feb 2024 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 12/02/24 | GSK | 15:26:43 | 12 Feb 2024 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 12/02/24 | GSK | 07:00:05 | 12 Feb 2024 | | GSK | US FDA Fast Track designation for bepirovirsen | GSK PLC | RNS |
| 06/02/24 | GSK | 07:10:01 | 6 Feb 2024 | | GSK | FDA accepts Arexvy filing for adults 50-59 at risk | GSK PLC | RNS |
| 06/02/24 | GSK | 07:05:00 | 6 Feb 2024 | | GSK | Shingrix 18+ at risk China filing review accepted | GSK PLC | RNS |
| 06/02/24 | GSK | 07:00:04 | 6 Feb 2024 | | GSK | GSK presents positive DREAMM-7 phase III data | GSK PLC | RNS |
| 01/02/24 | GSK | 15:30:00 | 1 Feb 2024 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 01/02/24 | GSK | 15:00:00 | 1 Feb 2024 | | GSK | Total Voting Rights | GSK PLC | RNS |
| 01/02/24 | GSK | 07:00:04 | 1 Feb 2024 | | GSK | Statement: Zantac (ranitidine) litigation | GSK PLC | RNS |
| 31/01/24 | GSK | 07:00:07 | 31 Jan 2024 | | GSK | Final Results | GSK PLC | RNS |
| 29/01/24 | GSK | 07:05:01 | 29 Jan 2024 | | GSK | EMA accepts Arexvy filing for adults 50-59 at risk | GSK PLC | RNS |
| 29/01/24 | GSK | 07:00:07 | 29 Jan 2024 | | GSK | European Commission authorises Omjjara in the EU | GSK PLC | RNS |
| 19/01/24 | GSK | 15:30:00 | 19 Jan 2024 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 17/01/24 | GSK | 15:30:00 | 17 Jan 2024 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 17/01/24 | GSK | 07:00:05 | 17 Jan 2024 | | GSK | GSK completes sale of shares in Haleon plc | GSK PLC | RNS |
| 16/01/24 | GSK | 16:40:18 | 16 Jan 2024 | | GSK | GSK announces intention to sell shares in Haleon | GSK PLC | RNS |
| 16/01/24 | GSK | 15:30:01 | 16 Jan 2024 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 10/01/24 | GSK | 07:00:01 | 10 Jan 2024 | | GSK | Nucala approved in China for use in severe asthma | GSK PLC | RNS |
| 09/01/24 | GSK | 07:00:04 | 9 Jan 2024 | | GSK | GSK enters agreement to acquire Aiolos Bio | GSK PLC | RNS |
| 02/01/24 | GSK | 15:00:01 | 2 Jan 2024 | | GSK | Total Voting Rights | GSK PLC | RNS |
| 21/12/23 | GSK | 15:30:00 | 21 Dec 2023 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 20/12/23 | GSK | 16:44:25 | 20 Dec 2023 | | GSK | Publication of EMTN Suppl.Prospcts | GSK PLC | RNS |
| 18/12/23 | GSK | 07:00:04 | 18 Dec 2023 | | GSK | Jemperli plus Zejula Trial Meets Endpoint | GSK PLC | RNS |
| 13/12/23 | GSK | 15:30:01 | 13 Dec 2023 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 12/12/23 | GSK | 07:00:03 | 12 Dec 2023 | | GSK | Japan accepts Arexvy filing for at risk adults | GSK PLC | RNS |
| 11/12/23 | GSK | 07:00:05 | 11 Dec 2023 | | GSK | Jemperli plus chemotherapy EU authorisation | GSK PLC | RNS |
| 04/12/23 | GSK | 15:02:10 | 4 Dec 2023 | | GSK | GSK publishes provisional 2024 dividend dates | GSK PLC | RNS |
| 01/12/23 | GSK | 15:00:01 | 1 Dec 2023 | | GSK | Total Voting Rights | GSK PLC | RNS |
| 30/11/23 | GSK | 09:00:01 | 30 Nov 2023 | | GSK | Block Listing Application | GSK PLC | RNS |
| 29/11/23 | GSK | 15:23:02 | 29 Nov 2023 | | GSK | Holding(s) in Company | GSK PLC | RNS |
| 27/11/23 | GSK | 07:00:04 | 27 Nov 2023 | | GSK | GSK announces positive DREAMM-7 headline results | GSK PLC | RNS |
| 21/11/23 | GSK | 15:30:00 | 21 Nov 2023 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 15/11/23 | GSK | 15:00:01 | 15 Nov 2023 | | GSK | Block listing Interim Review | GSK PLC | RNS |
| 13/11/23 | GSK | 15:30:01 | 13 Nov 2023 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 13/11/23 | GSK | 07:00:11 | 13 Nov 2023 | | GSK | GSK receives positive CHMP opinion for momelotinib | GSK PLC | RNS |
| 01/11/23 | GSK | 15:00:00 | 1 Nov 2023 | | GSK | Total Voting Rights | GSK PLC | RNS |
| 01/11/23 | GSK | 07:00:11 | 1 Nov 2023 | | GSK | 3rd Quarter Results | GSK PLC | RNS |
| 30/10/23 | GSK | 07:00:10 | 30 Oct 2023 | | GSK | Jemperli trial meets overall survival endpoint | GSK PLC | RNS |
| 26/10/23 | GSK | 07:00:11 | 26 Oct 2023 | | GSK | NMPA approves Vocabria+Rekambys in China | GSK PLC | RNS |
| 25/10/23 | GSK | 15:30:00 | 25 Oct 2023 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
